Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.45 · Revenue $0.00 · 1 analysts
Est. EPS $-1.20 · Revenue $300000.00 · 1 analysts
Est. EPS $-0.46 · Revenue $0.00 · 1 analysts
Est. EPS $-0.50 · Revenue $0.00 · 1 analysts
EPS $-0.11 · Revenue $2.73M
EPS $-35.21 · Revenue $226000.00
EPS $-5.92 · Revenue $56000.00
EPS $-22.57 · Revenue $226000.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $2.8M | +1134.5% | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $9.2M | +116.8% | +4.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | +5.6% | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -640.7% | +97.1% | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +328.7% | +101.4% | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-20.8M | +30.3% | +6.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -744.4% | +94.4% | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | — | — |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.72x | -66.9% | -40.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $10.6M | -57.5% | -23.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.82 vs 0.69 | +18.8% | -0.53 vs -0.34 | -58.2% |
| Revenue Surprise | $2.8M vs $2.8M | -0.4% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Pauza Charles David | officer: Chief Science Officer Virology | Stock Option (right to buy) | A | 97,000 | $0.68 |
| Jul 9, 2026 | CAUTREELS WERNER | director | Stock Option (right to buy) | A | 14,150 | $0.68 |
| Jul 9, 2026 | Savchuk Nikolay | director, officer: Chief Operating Officer | Stock Option (right to buy) | A | 93,000 | $0.68 |
| Jul 9, 2026 | STOVER JACK E | director | Stock Option (right to buy) | A | 14,150 | $0.68 |
| Jul 9, 2026 | Dukes Iain D. | director, officer: Chief Executive Officer | Stock Option (right to buy) | A | 274,000 | $0.68 |
Ladies and gentlemen, thank you for standing by. Welcome to the Traws Pharma conference call. Please note all participants are in listen-only mode until the question-and-answer session. As a reminder, this call is recorded. I would now like to turn the call over to John Fraunces, LifeSci Advisors.
Thank you, operator, and welcome, everyone, to Traws Pharma's Full Year 2025 Financial Results and Business Update Conference Call. This afternoon, Traws issued a press release reporting its 2025 financial results and provided a business update. If you have not yet seen this press release, it is available in the Investor Relations section of the company's website. Following my introduction, we will hear from Traws's Chief Executive Officer, Dr. Iain Dukes; and Chief Financial Officer, Charles Parker. Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Traws disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in this morning's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Traws's CEO, Dr. Iain Dukes.
Thanks, John, and thanks to everyone for joining us today. Over the last year, Traws has made substantial progress towards our objective of bringing our differentiated next-generation antiviral candidate for influenza to patients. This morning, Traws announced a private financing of $60 million. The private financing was supported by new and existing health care-focused investors. The capital from this financing positions Traws to advance the flu program through a human challenge study this summer while providing access to additional capital as we achieve further key milestones. Influenza is estimated to be a multibillion-dollar opportunity spanning prophylactic and therapeutic applications, including strategic government stockpiling and pandemic preparedness incentives. The human challenge study trial focused on flu prevention is an important step towards establishing the potential for tivoxavir marboxil as a potential best-in-class prophylactic agent for flu prevention. We intend to initiate the study this summer once we have approval received from the Medicines and Healthcare products Regulatory Agency, or MHRA, in the U.K. During today's call, we will provide an overview of development of our lead candidate, tivoxavir marboxil or tivoxavir for short, for influenza. Tivoxavir marboxil is an exciting next-generation investigational …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Iain D. Dukes DPHIL | Chief Executive Officer, Secretary & Director | USD 776,375 | — | 1958 | Active |
Charles David Pauza | Chief Scientific Officer of Virology | USD 701,307 | — | 1955 | Active |
Charles Parker | Chief Financial Officer | USD 676,291 | Male | 1981 | Active |
Victor Moyo | Chief Medical Officer of Oncology | USD 478,436 | — | 1969 | Active |
Nikolay Savchuk | Chief Operating Officer & Director | USD 476,000 | — | 1969 | Active |
Robert Redfield | Chief Medical Officer | — | — | 1952 | Active |
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $0.4871 and last traded at $0.4716. Approximately 94,244 shares were traded during trading, a decline of 31% from the average daily volume of 137,096 shares. The stock had previously closed at
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio.
